MSB - Mesoblast Limited
ASX
->
Healthcare
->
Biotechnology
Melbourne,
Australia
Type: Equity
MSB price evolution
MSB
| (in millions $) | 1 Dec 2023 | 31 Aug 2023 | 30 May 2023 | 3 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $77.55 | $71.32 | $48.8 | |
| Short term investments | ||||
| Net receivables | $2.89 | $3.85 | $1.39 | $0.02 |
| Inventory | ||||
| Total current assets | $26.01 | $21.9 | $14.6 | $14.12 |
| Long term investments | $0.83 | $0.83 | $1.76 | $2.03 |
| Property, plant & equipment | $5.5 | $5.5 | $6.49 | $7.12 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $26.01 | $21.9 | $14.6 | $14.12 |
| Current liabilities | ||||
| Accounts payable | $10.76 | $10.76 | $20.14 | $20.97 |
| Deferred revenue | ||||
| Short long term debt | $11.38 | $11.38 | $10.01 | $10.92 |
| Total current liabilities | $4.87 | $0.26 | $2.14 | $2.68 |
| Long term debt | $110.61 | $110.61 | $106.48 | $103.69 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.87 | $0.26 | $2.14 | $2.68 |
| Shareholders' equity | ||||
| Retained earnings | $21.14 | $21.64 | $12.46 | $11.44 |
| Other shareholder equity | $75.85 | $75.85 | $73.52 | $73.55 |
| Total shareholder equity | $508.73 | $508.73 | $501.84 | $482.17 |
| (in millions $) | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 | 30 Jun 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $71.32 | $60.45 | $136.38 | $128.93 |
| Short term investments | $0.25 | |||
| Net receivables | $6.53 | $4.4 | $4.84 | $1.57 |
| Inventory | ||||
| Total current assets | $81.66 | $69.84 | $148.23 | $136.55 |
| Long term investments | $1.76 | $1.76 | $2.08 | $1.87 |
| Property, plant & equipment | $6.49 | $9.96 | $12.14 | $10.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $669.42 | $662.14 | $744.72 | $733.6 |
| Current liabilities | ||||
| Accounts payable | $20.14 | $23.08 | $19.6 | $24.97 |
| Deferred revenue | ||||
| Short long term debt | $10.01 | $8.2 | $55.97 | $35.97 |
| Total current liabilities | $41.98 | $51.37 | $94.27 | $90.14 |
| Long term debt | $106.48 | $98.7 | $49.53 | $63.34 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $167.58 | $165.1 | $163.32 | $184.28 |
| Shareholders' equity | ||||
| Retained earnings | -$820.8 | -$738.92 | -$541.75 | -$463.43 |
| Other shareholder equity | $73.52 | $70.65 | -$39.79 | -$38.27 |
| Total shareholder equity | $501.84 | $497.04 | $581.4 | $549.33 |
| (in millions $) | 1 Dec 2023 | 31 Aug 2023 | 30 May 2023 | 3 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.9 | $9.89 | $1.85 | $7.74 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $0.81 | $0.71 | $0.83 | $2.43 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | $4.09 | $9.18 | $1.02 | $5.31 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 | 30 Jun 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.5 | $10.21 | $7.46 | $32.16 |
| Cost of revenue | $54.92 | $63.57 | $32.72 | $25.31 |
| Gross Profit | -$47.42 | -$53.36 | -$25.26 | $6.85 |
| Operating activities | ||||
| Research & development | $27.19 | $32.82 | $51.54 | $54.73 |
| Selling, general & administrative | $25.37 | $27.21 | $30.87 | $25.61 |
| Total operating expenses | $76.79 | $90.78 | $92.62 | $105.04 |
| Operating income | -$69.29 | -$80.57 | -$85.16 | -$72.89 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.21 | -$0.24 | -$0.82 | -$9.41 |
| Interest expense | -$19.44 | -$16.91 | ||
| Net income | ||||
| Net income | -$81.89 | -$91.35 | -$98.81 | -$77.94 |
| Income (for common shares) | -$81.89 | -$91.35 | -$98.81 | -$77.94 |
| (in millions $) | 1 Dec 2023 | 31 Aug 2023 | 30 May 2023 | 3 Mar 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | -$47.63 | |||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$47.63 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $8.95 | $3.78 | -$0.86 | -$33.76 |
| (in millions $) | 30 Jun 2023 | 30 Jun 2022 | 3 Mar 2022 | 2 Mar 2021 |
|---|---|---|---|---|
| Net income | -$81.89 | -$91.35 | $23.41 | |
| Operating activities | ||||
| Depreciation | $2.61 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$63.27 | -$65.78 | $20.81 | |
| Investing activities | ||||
| Capital expenditures | -$0.26 | -$0.16 | ||
| Investments | ||||
| Total cash flows from investing | -$0.19 | -$0.23 | $9.91 | $3.43 |
| Financing activities | ||||
| Dividends paid | -$37.52 | -$21.91 | ||
| Sale and purchase of stock | $88.64 | $0.21 | ||
| Net borrowings | -$2.66 | -$6.33 | ||
| Total cash flows from financing | $74.5 | -$9.87 | -$37.52 | -$21.91 |
| Effect of exchange rate | -$0.16 | |||
| Change in cash and equivalents | $10.87 | -$76.43 | $35.23 | $2.32 |
News
Fundamentals
| Market cap | $10.04M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 13.12M |
| Revenue | $24.38M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $19.60M |
| Revenue Q/Q | 129.86% |
| Revenue Y/Y | -18.51% |
| P/E ratio | 0.51 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.41 |
| P/B ratio | 0.02 |
| Book/Share | 32.99 |
| Cash/Share | N/A |
| EPS | $1.49 |
|---|---|
| ROA | 102.31% |
| ROE | 3.92% |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.34 |
| Quick ratio | N/A |